Year: 2024

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --...

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of...

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant...

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San...

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09,...

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

error: Content is protected !!